Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with Myelofibrosis from COMFORT-I

Clinical Lymphoma, Myeloma and Leukemia

Volumn 15, Issue 4, 2015, Pages 214-221.e1

  Mesa, Ruben A ^a   Verstovsek, Srdan ^b   Gupta, Vikas ^c   Mascarenhas, John O ^d   Atallah, Ehab ^e   Burn, Timothy ^f   Sun, William ^f   Sandor, Victor ^f   Gotlib, Jason ^g  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

^f Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

^g STANFORD CANCER INSTITUTE   (United States)

Author keywords

Albumin; Cachexia; Cholesterol; JAK inhibitor; Weight

Indexed keywords

ALBUMIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RUXOLITINIB; BIOLOGICAL MARKER; JANUS KINASE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY WEIGHT; CANCER SURVIVAL; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; MYELOFIBROSIS; MYELOFIBROSIS SYMPTOM ASSESSMENT FORM 2; NUTRITIONAL PARAMETERS; NUTRITIONAL STATUS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPLEEN SIZE; SPLENOMEGALY; SYMPTOM; THROMBOCYTE COUNT; TOTAL SYMPTOM SCORE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANATOMY AND HISTOLOGY; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; METABOLISM; ORGAN SIZE; PATHOLOGY; PRIMARY MYELOFIBROSIS; SPLEEN;

BIOMARKERS; BODY WEIGHT; CHOLESTEROL; HUMANS; JANUS KINASES; ORGAN SIZE; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; SERUM ALBUMIN; SPLEEN; TREATMENT OUTCOME;

EID: 84925412377     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.12.008     Document Type: Article

References (30)

1. F. Cervantes, B. Dupriez, and A. Pereira New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood 113 2009 2895 2901
2. A. Tefferi, T.L. Lasho, and T. Jimma One thousand patients with primary myelofibrosis: the Mayo Clinic experience Mayo Clin Proc 87 2012 25 33
3. A. Tefferi Myelofibrosis with myeloid metaplasia N Engl J Med 342 2000 1255 1265
4. S.A. Gregory, R.A. Mesa, R. Hoffman, and J.M. Shammo Clinical and laboratory features of myelofibrosis and limitations of current therapies Clin Adv Hematol Oncol 9 2011 1 16
5. R.A. Mesa, A. Green, and G. Barosi MPN-associated myelofibrosis (MPN-MF) Leuk Res 35 2011 12 13
6. R.A. Mesa, J. Niblack, and M. Wadleigh The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients Cancer 109 2007 68 76
7. R.A. Mesa, S. Schwager, and J. Huang Weight loss, splenomegaly, and hypocholesterolemia in myeloproliferative neoplasms: patterns and relevance from the pre JAK2 inhibitor era (abstract) Blood 114 2009 Abstract 3918
8. R.A. Mesa, J. Gotlib, and V. Gupta Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial J Clin Oncol 31 2013 1285 1292
9. N. Gangat, D. Caramazza, and R. Vaidya DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status J Clin Oncol 29 2011 392 397
10. R.A. Mesa The evolving treatment paradigm in myelofibrosis Leuk Lymphoma 54 2013 242 251
11. A. Quintás-Cardama, and S. Verstovsek Molecular pathways: JAK/STAT pathway: mutations, inhibitors, and resistance Clin Cancer Res 19 2013 1933 1940
12. S. Verstovsek, H. Kantarjian, and R.A. Mesa Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N Engl J Med 363 2010 1117 1127
13. N.C. Cross Genetic and epigenetic complexity in myeloproliferative neoplasms Hematology Am Soc Hematol Educ Program 2011 2011 208 214
14. J.M. Argiles, F.J. Lopez-Soriano, and S. Busquets Counteracting inflammation: a promising therapy in cachexia Crit Rev Oncog 17 2012 253 262
15. K.C. Fearon, D.J. Glass, and D.C. Guttridge Cancer cachexia: mediators, signaling, and metabolic pathways Cell Metab 16 2012 153 166
16. A. Tefferi, R. Vaidya, and D. Caramazza Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study J Clin Oncol 29 2011 1356 1363
17. H.J. Kim, H.J. Kim, and J. Yun Pathophysiological role of hormones and cytokines in cancer cachexia J Korean Med Sci 27 2012 128 134
18. M. Chojkier Inhibition of albumin synthesis in chronic diseases: molecular mechanisms J Clin Gastroenterol 39 2005 S143 S146
19. R.A. Mesa, J. Huang, and S. Schwager Hypocholesterolemia is independently associated with decreased survival in patients with primary myelofibrosis: an analysis of lipid profiles in 558 myeloproliferative patients (abstract) Blood 110 2007 Abstract 2548
20. N. Sulai, B. Mengistu, and N. Gangat Decreased levels of total or HDL cholesterol in primary myelofibrosis are associated with shortened survival: DIPSS-Plus independent prognostic value (abstract) Blood 120 2012 Abstract 2851
21. S. Verstovsek, R.A. Mesa, and J. Gotlib A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 2012 799 807
22. C. Harrison, J.J. Kiladjian, and H.K. Al-Ali JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 2012 787 798
23. S. Verstovsek, R.A. Mesa, and J. Gotlib Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I Haematologica 98 2013 1865 1871
24. F. Cervantes, A.M. Vannucchi, and J.J. Kiladjian Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis Blood 122 2013 4047 4053
25. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239
26. G. Franch-Arcas The meaning of hypoalbuminaemia in clinical practice Clin Nutr 20 2001 265 269
27. J.P. Nicholson, M.R. Wolmarans, and G.R. Park The role of albumin in critical illness Br J Anaesth 85 2000 599 610
28. R.A. Mesa, S. Schwager, and D. Radia The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis Leuk Res 33 2009 1199 1203
29. C. Gabay, and I. Kushner Acute-phase proteins and other systemic responses to inflammation N Engl J Med 340 1999 448 454
30. K.C. Fearon, A.C. Voss, D.S. Hustead for the Cancer Cachexia Study Group Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis Am J Clin Nutr 83 2006 1345 1350